BR112023002951A2 - Compostos de fosfolipídio e usos destes - Google Patents

Compostos de fosfolipídio e usos destes

Info

Publication number
BR112023002951A2
BR112023002951A2 BR112023002951A BR112023002951A BR112023002951A2 BR 112023002951 A2 BR112023002951 A2 BR 112023002951A2 BR 112023002951 A BR112023002951 A BR 112023002951A BR 112023002951 A BR112023002951 A BR 112023002951A BR 112023002951 A2 BR112023002951 A2 BR 112023002951A2
Authority
BR
Brazil
Prior art keywords
compounds
phospholipid compounds
phospholipid
alone
formula
Prior art date
Application number
BR112023002951A
Other languages
English (en)
Inventor
E Lazerwith Scott
William MEDLEY Jonathan
A Morganelli Philip
Naduthambi Devan
P Stratton Thomas
Wang Peiyuan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112023002951A2 publication Critical patent/BR112023002951A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS DE FOSFOLIPÍDIO E USOS DESTES. A presente invenção refere-se a compostos e métodos de uso dos ditos compostos, isoladamente ou em combinação com agentes adicionais, e composições farmacêuticas dos ditos compostos para o tratamento de infecções virais (Fórmula (I)).
BR112023002951A 2020-08-24 2021-08-23 Compostos de fosfolipídio e usos destes BR112023002951A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069449P 2020-08-24 2020-08-24
US202063092386P 2020-10-15 2020-10-15
US202163151509P 2021-02-19 2021-02-19
PCT/US2021/047145 WO2022046631A1 (en) 2020-08-24 2021-08-23 Phospholipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112023002951A2 true BR112023002951A2 (pt) 2023-03-21

Family

ID=77802251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002951A BR112023002951A2 (pt) 2020-08-24 2021-08-23 Compostos de fosfolipídio e usos destes

Country Status (16)

Country Link
US (2) US11773122B2 (pt)
EP (1) EP4200301A1 (pt)
JP (1) JP2023538442A (pt)
KR (1) KR20230057419A (pt)
CN (1) CN116323630A (pt)
AU (2) AU2021330835B2 (pt)
BR (1) BR112023002951A2 (pt)
CA (1) CA3188373A1 (pt)
CL (1) CL2023000524A1 (pt)
CO (1) CO2023001953A2 (pt)
CR (1) CR20230100A (pt)
DO (1) DOP2023000037A (pt)
IL (1) IL300412A (pt)
MX (1) MX2023002233A (pt)
TW (2) TW202337471A (pt)
WO (1) WO2022046631A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
EP4355755A1 (en) 2021-06-14 2024-04-24 Venatorx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
US20230212199A1 (en) * 2021-08-18 2023-07-06 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN115251042B (zh) * 2022-09-08 2023-06-02 安徽科技学院 一种家禽精液稀释缓冲液及其制备和家禽精液冷存方法
WO2024120464A1 (zh) * 2022-12-09 2024-06-13 深圳市塔吉瑞生物医药有限公司 核苷酸类似物及其组合物及用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0262876B1 (en) 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
CN1414854B (zh) 1999-12-03 2015-08-19 加利福尼亚大学圣地亚哥分校董事会 膦酸酯化合物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100854398B1 (ko) 2000-05-26 2008-08-26 이데닉스 (케이만) 리미티드 베타-ｌ-2'-데옥시-뉴클레오사이드를 이용한 델타형 간염바이러스 감염의 치료방법
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
NZ596107A (en) 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
JP5547069B2 (ja) 2007-08-03 2014-07-09 バイオトロン リミテッド Ｃ型肝炎抗ウイルス組成物および方法
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8962580B2 (en) 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
WO2011059021A1 (ja) 2009-11-11 2011-05-19 大日本住友製薬株式会社 ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
BR112015004113A2 (pt) 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
RS57796B1 (sr) 2013-03-15 2018-12-31 Univ California Diestri acikličnog nukleozid fosfonata
EP3013340B9 (en) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
SG11201605970QA (en) 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016023877A1 (en) 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016107832A1 (en) 2014-12-30 2016-07-07 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CN107208102B (zh) 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 重组hbv cccdna、其产生方法及其用途
EP3256471B1 (en) 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
MX2019009443A (es) 2017-02-08 2019-12-16 Biotron Ltd Metodos para tratar la influenza.
US10682368B2 (en) * 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018312224A1 (en) 2017-07-31 2020-02-27 January Therapeutics, Inc. Organophosphate derivatives
KR20200098483A (ko) 2017-09-18 2020-08-20 얀센 바이오파마, 인크. 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체
US20210060051A1 (en) 2017-12-27 2021-03-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
KR20200143365A (ko) 2018-03-02 2020-12-23 재뉴어리 테라퓨틱스, 인크. 나노입자 조성물
TW202315607A (zh) * 2020-02-18 2023-04-16 美商基利科學股份有限公司 抗病毒化合物
CN116264827A (zh) 2020-07-24 2023-06-16 加利福尼亚大学董事会 抗病毒前药、药物制剂和方法
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
EP4355755A1 (en) 2021-06-14 2024-04-24 Venatorx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs

Also Published As

Publication number Publication date
DOP2023000037A (es) 2023-07-09
US11773122B2 (en) 2023-10-03
TWI807399B (zh) 2023-07-01
CL2023000524A1 (es) 2023-09-29
CN116323630A (zh) 2023-06-23
CA3188373A1 (en) 2022-03-03
US20230250117A1 (en) 2023-08-10
KR20230057419A (ko) 2023-04-28
AU2024201573A1 (en) 2024-04-04
IL300412A (en) 2023-04-01
TW202337471A (zh) 2023-10-01
US20240025932A1 (en) 2024-01-25
TW202222323A (zh) 2022-06-16
EP4200301A1 (en) 2023-06-28
CR20230100A (es) 2023-04-28
AU2021330835B2 (en) 2023-12-14
AU2021330835A1 (en) 2023-03-30
CO2023001953A2 (es) 2023-03-17
US20220081455A1 (en) 2022-03-17
WO2022046631A1 (en) 2022-03-03
MX2023002233A (es) 2023-03-15
JP2023538442A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022012625A2 (pt) Compostos moduladores de diacilglicerol quinase
BR112018075663A2 (pt) compostos e composições para a inibição da atividade de shp2
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112019009529A2 (pt) novos derivados de quinolina
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112021011325A2 (pt) Derivados de rapamicina
CO2022000270A2 (es) Inhibidores de enzimas